Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils.

[1]  M. Zeller,et al.  Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. , 2005, Journal of medicinal chemistry.

[2]  M. Redinbo,et al.  Mammalian carboxylesterases: from drug targets to protein therapeutics. , 2005, Drug discovery today.

[3]  P. Beroza,et al.  Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. , 2004, Molecular pharmacology.

[4]  M. Redinbo,et al.  Human carboxylesterase 1: from drug metabolism to drug discovery. , 2003, Biochemical Society transactions.

[5]  Max Dobler,et al.  Multidimensional QSAR: Moving from three‐ to five‐dimensional concepts , 2002 .

[6]  Max Dobler,et al.  5D-QSAR: the key for simulating induced fit? , 2002, Journal of medicinal chemistry.

[7]  M. Wierdl,et al.  Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. , 2001, Molecular pharmacology.

[8]  C. Morton,et al.  Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression , 2000, Molecular biotechnology.

[9]  C. Morton,et al.  Proficient metabolism of irinotecan by a human intestinal carboxylesterase. , 2000, Cancer research.

[10]  Steven L. Dixon,et al.  Bioactive Diversity and Screening Library Selection via Affinity Fingerprinting , 1998, J. Chem. Inf. Comput. Sci..

[11]  T. Langmann,et al.  Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. , 1997, Biochemical and biophysical research communications.

[12]  F. Oehme.  Goodman and Gilman 's: The pharmacological basis of therapeutics , 1996 .

[13]  J R Cashman,et al.  Pharmacokinetics and molecular detoxication. , 1996, Environmental health perspectives.

[14]  M. Frisch,et al.  Ab Initio Calculation of Vibrational Absorption and Circular Dichroism Spectra Using Density Functional Force Fields , 1994 .

[15]  H. Chapman,et al.  A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. , 1991, The Journal of biological chemistry.

[16]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[17]  G. A. Petersson,et al.  A complete basis set model chemistry. I. The total energies of closed‐shell atoms and hydrides of the first‐row elements , 1988 .

[18]  I. Silman,et al.  Microtiter assay for acetylcholinesterase. , 1987, Analytical biochemistry.

[19]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[20]  M. Weiss,et al.  The catalytic oxidation of benzoin to benzil. , 1948, Journal of the American Chemical Society.

[21]  Michael Müller,et al.  Enantioselective Synthesis of α‐Hydroxy Ketones via Benzaldehyde Lyase‐Catalyzed C−C Bond Formation Reaction , 2002 .

[22]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[23]  John Leyden. Webb,et al.  Enzyme and metabolic inhibitors , 1963 .

[24]  J. L. Webb.  General principles of inhibition , 1963 .